Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 7, 2013, Pages 841-846

  Lindström, Lina ^a   Hultcrantz, Rolf ^a   Boberg, Kirsten Muri ^b   Friis Liby, Ingalill ^c   Bergquist, Annika ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bile Acid; Follow up Study; Liver Failure; Randomized Placebo Controlled Clinical Trial

Indexed keywords

ALKALINE PHOSPHATASE; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE DUCT CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

ADULT; ALKALINE PHOSPHATASE; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROGNOSIS; SURVIVAL ANALYSIS; URSODEOXYCHOLIC ACID;

EID: 84879239968     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.032     Document Type: Article

References (25)

1. Culver E.L., Chapman R.W. Systematic review: management options for primary sclerosing cholangitis and its variant forms-IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther 2011, 33:1273-1291.
2. Broomé U., Olsson R., Lööf L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610-615.
3. de Valle M., Björnsson E., Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012, 32:441-448.
4. Cullen S., Rust C., Fleming K., et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008, 48:792-800.
5. Martinez J.D., Stratagoules E.D., LaRue J.M., et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998, 31:111-118.
6. Parés A., Caballería L., Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006, 130:715-720.
7. Gong Y., Huang Z.B., Christensen E., et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008, 3. CD000551.
8. Lee J., Belanger A., Doucette J.T., et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5:1313-1315.
9. Kuiper E.M., Hansen B.E., Metselaar H.J., et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol 2010, 10:144.
10. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267. European Association for the Study of the Liver.
11. Kuiper E.M., Hansen B.E., de Vries R.A., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136:1281-1287.
12. Corpechot C., Chazouillères O., Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011, 55:1361-1367.
13. Angulo P., Lindor K.D., Therneau T.M., et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999, 19:115-121.
14. Lindor K.D. Ursodiol for primary sclerosing cholangitis: Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
15. Chapman R.W. Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid. Dig Liver Dis 2003, 35:306-308.
16. Olsson R., Boberg K.M., de Muckadell O.S., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-1472.
17. Chapman R.W. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?. Hepatology 2009, 50:671-673.
18. Lindor K.D., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
19. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
20. Tischendorf J., Hecker H., Krüger M., et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102:107-114.
21. Aadland E., Schrumpf E., Fausa O., et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987, 22:655-664.
22. Stanich P.P., Björnsson E., Gossard A.A., et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011, 43:309-313.
23. Kim W.R., Poterucha J.J., Wiesner R.H., et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999, 29:1643-1648.
24. Boberg K., Rocca G., Egeland T., et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002, 35:652-657.
25. Barnabas A., Chapman R.W. Primary sclerosing cholangitis: is any treatment worthwhile?. Curr Gastroenterol Rep 2012, 14:17-24.